Response of Pediatric Uveitis to Tumor Necrosis Factor- Inhibitors (original) (raw)
Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey
Graciela Espada
The Journal of rheumatology, 2007
View PDFchevron_right
Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol
Graciela Espada
The Journal of Rheumatology
View PDFchevron_right
Anti-TNF therapy for juvenile idiopathic arthritis-related uveitis
G. Nascimbeni, Barbara Arcidiacono, Dr Barbara Parolini, Ciro Costagliola
Drug Design, Development and Therapy, 2014
View PDFchevron_right
Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: Adalimumab as starting anti-TNF-α therapy in childhood chronic uveitis
Fulvio Parentin
Pediatric Rheumatology, 2013
View PDFchevron_right
Juvenile idiopathic arthritis-associated uveitis in the era of biological therapy: how the disease changed in 14 years of observation in a tertiary referral center in Rome (Italy)
Annalisa di Coste
2021
View PDFchevron_right
2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis–Associated Uveitis
James Reston
Arthritis & Rheumatology
View PDFchevron_right
Clinical management algorithm of uveitis associated with juvenile idiopathic arthritis: interdisciplinary panel consensus
Beatriz Bravo
Rheumatology International, 2015
View PDFchevron_right
Does switching anti-TNFα biologic agents represent an effective option in childhood chronic uveitis: the evidence from a systematic review and meta-analysis approach
Gabriele Simonini
Seminars in arthritis and rheumatism, 2014
View PDFchevron_right
Longterm Safety and Efficacy of Adalimumab and Infliximab for Uveitis Associated with Juvenile Idiopathic Arthritis
Silvana Guerriero
The Journal of rheumatology, 2018
View PDFchevron_right
Managing juvenile idiopathic arthritis–associated uveitis
Andrew Dick
Survey of Ophthalmology, 2016
View PDFchevron_right
Safety and Efficacy of Infliximab and Adalimumab for Refractory Uveitis in Juvenile Idiopathic Arthritis: 1-year Followup Data from the Italian Registry
Riccardo de marco
The Journal of Rheumatology, 2013
View PDFchevron_right
Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis
Pekka Lahdenne
Rheumatology, 2007
View PDFchevron_right
PReS-FINAL-2063: Proposed criteria for activity, damage and impact of juvenile idiopathic arthritis associated uveitis: consensus effort from the multinational interdisciplinary working group for uveitis in childhood (MIWGUC)
Ivan Foeldvari
Pediatric Rheumatology, 2013
View PDFchevron_right
Prevalence and outcome of uveitis in a regional cohort of patients with juvenile rheumatoid arthritis
Carlos Rose
Journal of Aapos, 1998
View PDFchevron_right
Usefulness of Adalimumab in the Treatment of Refractory Uveitis Associated with Juvenile Idiopathic Arthritis
Jordi Antón
Mediators of Inflammation, 2013
View PDFchevron_right
Favorable response to high-dose infliximab for refractory childhood uveitis
Deborah Levy
Ophthalmology, 2006
View PDFchevron_right
Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis
Ivan Foeldvari
Rheumatology International, 2011
View PDFchevron_right
Juvenile idiopathic arthritis-associated uveitis
Nisha Acharya
Current Opinion in Ophthalmology, 2010
View PDFchevron_right
Uveitis associated with juvenile idiopathic arthritis
Muhammad Ziyad Al Fajar
2015
View PDFchevron_right
Proposed outcome measures for prospective clinical trials in juvenile idiopathic arthritis-associated uveitis: A consensus effort from the multinational interdisciplinary working group for uveitis in childhood
Clive Edelsten
Arthritis Care & Research, 2012
View PDFchevron_right
Comparable Efficacy of Abatacept Used as First-line or Second-line Biological Agent for Severe Juvenile Idiopathic Arthritis-related Uveitis
Maria Alessio
The Journal of rheumatology, 2016
View PDFchevron_right
Predictive factors and biomarkers for the 2-year outcome of uveitis in juvenile idiopathic arthritis: data from the Inception Cohort of Newly diagnosed patients with Juvenile Idiopathic Arthritis (ICON-JIA) study
Claudia Sengler
Rheumatology, 2018
View PDFchevron_right
Recent advances in uveitis of juvenile idiopathic arthritis
Anneli Savolainen
Survey of Ophthalmology, 2003
View PDFchevron_right
Uveitis Associated with Juvenile Idiopathic Arthritis, our Observations
almira ćosićkić
View PDFchevron_right